Health Canada expands Nutrasource Controlled Drugs & Substances Dealer’s License

Health Canada has approved an amendment to a Controlled Drugs and Substances Dealer’s License the agency issued to Nutrasource Pharmaceutical and Nutraceutical Services earlier this year.

Health Canada has approved an amendment to a Controlled Drugs and Substances Dealer’s License the agency issued to Nutrasource Pharmaceutical and Nutraceutical Services (Guelph, ON, Canada). The license was expanded to include controlled psychedelic and psychostimulant drugs and pain management drugs such as psilocybin, psilocin, ketamine, LSD, methamphetamines, synthetic cannabinoids, opioids, and DMT.

“This initiative is a natural progression building and diversifying our portfolio of licences including our Institution-Wide Cannabis Research Licence and Cage Level Security Licence. We are pleased to continue supporting our current and future clients in the areas of pharmaceutical development with botanical agents, psychedelics, and opioid alternatives” said Joshua Baisley, vice president, Clinical Design and Delivery for Nutrasource, in a press release.

The new approval will enable Nutrasource clients to conduct early stage clinical studies, including Bioavailability / Bioequivalence studies, proof of concept studies on many novel controlled substances in Canada. The Security Level 5 Licence allows clinical trials for safety, tolerability, characterization and efficacy for an expanded list of controlled drugs and substances.

“Working with sponsors in the Natural Health Product industry, we often see a transition into the pharmaceutical space as an avenue for innovation. Obtaining this license further fulfills Nutrasource’s mission of helping health companies launch scientifically substantiated products and aligns with our expanded pharmaceutical regulatory services,” said Tania John, vice president, NHP & Pharmaceutical Regulatory Sciences for Nutrasource. “Ultimately, this higher level of security allows us to better serve our clinical and regulatory clients, including those interested or already in the controlled drugs and substances sector.”